Synlogic (NASDAQ:SYBX) is pioneering the development and commercialization of a promising and innovative field known as synthetic biotics. Harnessing the power of genetically engineered microbes, Synlogic's projects aim to tackle a range of challenges in the medical and health sectors. Their work includes groundbreaking approaches to treat metabolic disorders, infections, and other diseases by manipulating the functions of living cells to perform therapeutic tasks. Their objective is centered on transforming the lives of patients by advancing the science of synthetic biology to produce living medicines that act in a precise, controlled fashion to treat disease at its source. Synlogic's dedication to innovation reflects their commitment to addressing unmet medical needs through the novel realm of synthetic biotics.